The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Treatment of Multiple Sclerosis: A Review
Open accessAbstract
Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of the central nervous system, and the leading cause of nontraumatic neurological disability in young adults. Effective management requires a multifaceted approach to control acute attacks, manage progressive worsening, and remediate bothersome or disabling symptoms associated with this illness. Remarkable advances in treatment of all forms of MS, and especially for relapsing disease, have favorably changed the long-term outlook for many patients. There also has been a conceptual shift in understanding the immune pathology of MS, away from a purely T-cell-mediated model to recognition that B cells have a key role in pathogenesis. The emergence of higher-efficacy drugs requiring less frequent administration have made these preferred options in terms of tolerability and adherence. Many experts now recommend use of these as first-line treatment for many patients with early disease, before permanent disability is evident.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It may also partly explain why immunosuppressive therapies have thus far had little or no effect on disability accumulation in progressive MS trials4.”
From Locus for severity implicates CNS resilience in progression of multiple sclerosis (2023) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“While disease-modifying therapies have significantly improved prognosis for relapsing forms of multiple sclerosis (RMS), effective treatments for the progressive, neurodegenerative phase are lacking.”
From Insights and challenges on animal models for progressive multiple sclerosis (2026) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Most DMTs are approved for treatment of relapsing MS (RMS) [17], a smaller number have shown benefit in some SPMS populations [19, 22, 23], but only one DMT has shown efficacy for treatment of PPMS, underlining the unmet need of treatment options for these patients [20] (Table 2).”
From Insights and challenges on animal models for progressive multiple sclerosis (2026) · cites this paper as [17]
In the citing paper
“For example, IFN-γ has been proposed to play both stimulatory and suppressive roles in cancer, and type I IFNs are used both as an immunosuppressant to treat multiple sclerosis and as immunostimulatory adjuvant treatments for cancer (for example melanoma) and chronic viral infection (for example HCV)48–50.”
From Causal identification of single-cell experimental perturbation effects with CINEMA-OT (2023) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30470-2 · Cited by 8,167
New Multiple Sclerosis Phenotypic Classification
LUBLIN, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,277
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdová, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., LUBLIN, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,433
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E. W., O'Connor, P. W., Polman, C. H., Hohlfeld, R., Calabresi, P. A., Selmaj, K. W., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,670
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. Μ., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,446
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationOral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comı, G., Hartung, H., Khatri, B. O., Montalbán, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,220
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,144
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021
Self-citationOcrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905
Self-citationPlacebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar‐Or, A., Giovannoni, G., Selmaj, K. W., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,765
Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
Yednock, T. A., Cannon, C., Fritz, L. C., Sánchez‐Madrid, F., Steinman, L., & Karin, N. (1992) · Nature · doi:10.1038/356063a0 · Cited by 1,737
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
Johnson, K., Brooks, B., Cohen, J. A., Ford, C., Goldstein, J., Lisak, R., Myers, L., Panitch, H., Rose, J., Schiffer, R., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,667
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdová, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206328 · Cited by 1,371
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E. W., LUBLIN, F. D., Weinstock‐Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,342
Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity
Browne, P., Chandraratna, D., Angood, C., Tremlett, H., Baker, C., Taylor, B. V., & Thompson, A. J. (2014) · Neurology · doi:10.1212/wnl.0000000000000768 · Cited by 1,223 · cited 1×
“(2) B cell rich lymphoid aggregates in the meninges, often in deep sulci, with underlying cortical demyelination and neuronal loss.”
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198
Girard, M., Duquette, P., & Sibley, W. A. (1993) · Cited by 1,197
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155
The prevalence of MS in the United States
Wallin, M. T., Culpepper, W. J., Campbell, J. D., Nelson, L. M., Langer-Gould, A. M., Marrie, R. A., Cutter, G., Kaye, W., Wagner, L., Tremlett, H. L., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007035 · Cited by 1,148
Wallin, M. T., Culpepper, W. J., Nichols, E., Bhutta, Z. A., Gebrehiwot, T. T., Hay, S. I., Khalil, I. A., Krohn, K. J., Liang, X., Naghavi, M., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30443-5 · Cited by 1,134
Harrison's Principles of Internal Medicine
Massarelli, J. J. (1984) · JAMA · doi:10.1001/jama.1984.03340300091039 · Cited by 1,132
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
The CAMMS Trial Investigators (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802670 · Cited by 1,021
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Giovannoni, G., Comı, G., Cook, S. D., Rammohan, K. W., Rieckmann, P., Sørensen, P. S., Vermersch, P., Chang, P., Hamlett, A., Musch, B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0902533 · Cited by 1,021
Multiple Sclerosis: Current Knowledge and Future Outlook
Kamm, C. P., Uitdehaag, B. M. J., & Polman, C. H. (2014) · European Neurology · doi:10.1159/000360528 · Cited by 1,011
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
O'Connor, P. W., Wolinsky, J. S., Confavreux, C., Comı, G., Kappos, L., Olsson, T. P., Benzerdjeb, H., Truffinet, P., Wang, L., Miller, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014656 · Cited by 989
Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30475-6 · Cited by 942
Self-citationNatural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 901 · cited 1×
“2020;383(6):546–557 [PubMed: 32757523] 28.”
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
Filippi, M., Rocca, M. A., Ciccarelli, O., De Stefano, N., Evangelou, N., Kappos, L., Rovira, A., Sastre-Garriga, J., Tintorè, M., Frederiksen, J. L., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00393-2 · Cited by 880
Calabresi, P. A., Radue, E. W., Goodin, D. S., Jeffery, D., Rammohan, K. W., Reder, A. T., Vollmer, T. L., Agius, M. A., Kappos, L., Stites, T. E., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70049-3 · Cited by 845
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Hauser, S. L., Bar‐Or, A., Cohen, J. A., Comı, G., Correale, J. D., Coyle, P. K., Cross, A. H., Seze, J. D., Leppert, D., Montalbán, X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917246 · Cited by 765
Self-citationPathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis
Lassmann, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03116 · Cited by 711
Kappos, L., Wolinsky, J. S., Giovannoni, G., Arnold, D. L., Wang, Q., Bernasconi, C., Model, F., Koendgen, H., Manfrini, M., Belachew, S. M., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1568 · Cited by 696
Self-citationPRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS
The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group (2001) · Neurology · doi:10.1212/wnl.56.12.1628 · Cited by 570
Johnson, K. P., Brooks, B., Cohen, J. A., Ford, C. C., Goldstein, J. M., Lisak, R. P., Myers, L. W., PANITCH, H. S., ROSE, J. W., Schiffer, R. B., et al. (1998) · Neurology · doi:10.1212/wnl.50.3.701 · Cited by 509
Steinman, L., & Zamvil, S. S. (2006) · Annals of Neurology · doi:10.1002/ana.20913 · Cited by 479
PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
Francis, G., Hughes, R. A., King, J. O., Mitchell, P. I., Joubert, J.-M., McLeod, J., Parker, G., Pollard, J. D., Sindic, C., Duprez, T. P. J., et al. (2001) · DIAL (Catholic University of Leuven) · doi:10.25405/ncl.34089345 · Cited by 472
Silent progression in disease activity–free relapsing multiple sclerosis
Cree, B., Hollenbach, J. A., Bove, R. M., Kirkish, G., Sacco, S., Caverzasi, E., Bischof, A., Gundel, T. J., Zhu, A. H., Papinutto, N., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25463 · Cited by 468
Self-citationScannevin, R. H., Chollate, S., Jung, M.-Y., Shackett, M. N., Patel, H., Bista, P., Zeng, W., Ryan, S. T., Yamamoto, M. P., Lukashev, M., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.190132 · Cited by 461
Reassessing B cell contributions in multiple sclerosis
Li, R., Patterson, K. R., & Bar‐Or, A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0135-x · Cited by 417
The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain
Haider, L., Zrzavy, T., Hametner, S., Höftberger, R., Bagnato, F., Grabner, G., Trattnig, S., Pfeifenbring, S., Brück, W., & Lassmann, H. (2016) · Brain · doi:10.1093/brain/awv398 · Cited by 400
Calabresi, P. A., Kieseier, B. C., Arnold, D. L., Balcer, L. J., Boyко, A., Pelletier, J., Liu, S., Zhu, Y., Seddighzadeh, A., Hung, S., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70068-7 · Cited by 396
B cells in autoimmune and neurodegenerative central nervous system diseases
Sabatino, J. J., Pröbstel, A., & Zamvil, S. S. (2019) · Nature reviews. Neuroscience · doi:10.1038/s41583-019-0233-2 · Cited by 361
The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis
Kieseier, B. C. (2011) · CNS Drugs · doi:10.2165/11591110-000000000-00000 · Cited by 327
Ho, P., Koendgen, H., Campbell, N., Haddock, B., Richman, S., & Chang, I. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30282-x · Cited by 319
Comı, G., Kappos, L., Selmaj, K. W., Bar‐Or, A., Arnold, D. L., Steinman, L., Hartung, H., Montalbán, X., Havrdová, E., Cree, B., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30239-x · Cited by 297
Self-citationCohen, J. A., Comı, G., Selmaj, K. W., Bar‐Or, A., Arnold, D. L., Steinman, L., Hartung, H., Montalbán, X., Havrdová, E., Cree, B., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30238-8 · Cited by 290
Self-citationB‐cell Therapy for Multiple Sclerosis: Entering an era
Greenfield, A. L., & Hauser, S. L. (2017) · Annals of Neurology · doi:10.1002/ana.25119 · Cited by 278
Self-citationvan Oosten, B. W., Lai, M., Hodgkinson, S. J., Barkhof, F., Miller, D., MOSELEY, I. F., Thompson, A. J., Rudge, P., McDougall, A., McLeod, J., et al. (1997) · Neurology · doi:10.1212/wnl.49.2.351 · Cited by 262
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis
Rudick, R. A., Goodkin, D. E., Jacobs, L. D., Cookfair, D. L., Herndon, R. M., Richert, J. R., Salazar, A. Μ., Fischer, J. S., Granger, C. V., Simon, J. H., et al. (1997) · Neurology · doi:10.1212/wnl.49.2.358 · Cited by 232
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
Ryerson, L. Z., Foley, J. F., Chang, I., Kister, I., Cutter, G., Metzger, R. R., Goldberg, J. D., Li, X., Riddle, E. L., Smirnakis, K. V., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008243 · Cited by 199
Cadavid, D., Wolansky, L. J., Skurnick, J., Lincoln, J. A., Cheriyan, J., Szczepanowski, K., Kamin, S. S., Pachner, A. R., Halper, J., & Cook, S. D. (2009) · Neurology · doi:10.1212/01.wnl.0000345970.73354.17 · Cited by 184
Page, E. L., Veillard, D., Laplaud, D. A., Hamonic, S., Wardi, R., Lebrun‐Frénay, C., Zagnoli, F., Wiertlewski, S., Deburghgraeve, V., Coustans, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61137-0 · Cited by 182
Glatiramer Acetate in the Treatment of Multiple Sclerosis
Lalive, P. H., Neuhaus, O., Benkhoucha, M., Burger, D., Hohlfeld, R., Zamvil, S. S., & Weber, M. S. (2011) · CNS Drugs · doi:10.2165/11588120-000000000-00000 · Cited by 177
Kappos, L., Butzkueven, H., Wiendl, H., Spelman, T., Pellegrini, F., Chen, Y., Dong, Q., Koendgen, H., Belachew, S. M., Trojano, M., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517709619 · Cited by 161
Symptomatic Treatment of Multiple Sclerosis
Henze, T., Rieckmann, P., & Toyka, K. V. (2006) · European Neurology · doi:10.1159/000095699 · Cited by 158
The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis [RETIRED]
Goodin, D. S., Arnason, B. G. W., Coyle, P. K., Frohman, E. M., & Paty, D. W. (2003) · Neurology · doi:10.1212/01.wnl.0000095425.84407.39 · Cited by 156
Massacesi, L., Genain, C. P., Lee‐Parritz, D. E., Letvin, N. L., Canfield, D. E., & Hauser, S. L. (1995) · Annals of Neurology · doi:10.1002/ana.410370415 · Cited by 137
Self-citationThe EVOLVE-MS-2 Study Group, Naismith, R. T., Wundes, A., Ziemssen, T., Jasińska, E., Freedman, M. S., Lembo, A. J., Selmaj, K. W., Bidollari, I., Chen, H., et al. (2020) · CNS Drugs · doi:10.1007/s40263-020-00700-0 · Cited by 133
Sørensen, P. S., & Blinkenberg, M. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285615601933 · Cited by 129
Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings
Kappos, L., Cohen, J. A., Collins, W., de Vera, A., Zhang-Auberson, L., Ritter, S., von Rosenstiel, P., & Francis, G. (2014) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2014.03.002 · Cited by 121
4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review
Jensen, H. B., Ravnborg, M. H., Dalgas, U., & Stenager, E. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613512712 · Cited by 117
Cohen, J. A., Baldassari, L. E., Atkins, H. L., Bowen, J. D., Bredeson, C., Carpenter, P. A., Corboy, J. R., Freedman, M. S., Griffith, L. M., Lowsky, R., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.02.014 · Cited by 108
The Charcot Lecture | Beating MS: A story of B cells, with twists and turns
Hauser, S. L. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514561911 · Cited by 100
Self-citationImmunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis
Galetta, S. L., Markowitz, C., & Lee, A. G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.19.2161 · Cited by 89
Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15
Kappos, L., Kühle, J., Multanen, J., Kremenchutzky, M., di Cantogno, E. V., Cornelisse, P., Lehr, L., Casset‐Semanaz, F., Issard, D., & Uitdehaag, B. M. J. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-310024 · Cited by 83
Schneider, S. A., & Deuschl, G. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0230-5 · Cited by 81
An open trial of OKT3 in patients with multiple sclerosis
Weinshenker, B. G., Bass, B., Karlik, S. J., Ebers, G. C., & Rice, G. P. (1991) · Neurology · doi:10.1212/wnl.41.7.1047 · Cited by 77
Korzhova, J. E., Bakulin, I. S., Sinitsyn, D. O., Poydasheva, A. G., Suponeva, N. A., Zakharova, M. N., & Пирадов, М. А. (2018) · European Journal of Neurology · doi:10.1111/ene.13877 · Cited by 71
Mills, E. A., & Mao‐Draayer, Y. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518775550 · Cited by 64
A comprehensive person-centered approach to adult spastic paresis: a consensus-based framework
Turner‐Stokes, L. F., Ashford, S. A., Esquenazi, A., Wissel, J., Ward, A. B., Francisco, G. E., Laíns, J., Suputtitada, A., SERRANO, S. E., Baguley, I. J., et al. (2018) · European Journal of Physical and Rehabilitation Medicine · doi:10.23736/s1973-9087.17.04808-0 · Cited by 61
Laroni, A., Brogi, D., Morra, V. B., Guidi, L., Pozzilli, C., Comi, G., Lugaresi, A., Turrini, R., Raimondi, D., Uccelli, A., et al. (2014) · BMC Neurology · doi:10.1186/1471-2377-14-65 · Cited by 53
Acute Multiple Sclerosis Relapse
Berkovich, R. (2016) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000330 · Cited by 49
Hauser, S. L., Kappos, L., Montalbán, X., Hughes, R. A., Koendgen, H., McNamara, J., Pradhan, A., Wormser, D., & Wolinsky, J. S. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.10.102 · Cited by 22
Self-citationMartinꝉ, R. (1997) · Springer eBooks · doi:10.1007/978-3-7091-6844-8_6 · Cited by 18
Hauser, S. L., Kappos, L., Montalbán, X., Craveiro, L., Hughes, R. A., McNamara, J., Pradhan, A., Wormser, D., Koendgen, H., & Wolinsky, J. S. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.10.313 · Cited by 11
Self-citation
Cited by
Sorted by citations
Benkert, P., Meier, S., Schaedelin, S., Manouchehrinia, A., Yaldizli, Ö., Maceski, A., Oechtering, J., Achtnichts, L., Conen, D., Derfuss, T., et al. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00009-6 · Cited by 657
Teleanu, R. I., Niculescu, A.-G., Roza, E., Vladâcenco, O. A., Grumezescu, A. M., & Teleanu, D. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115954 · Cited by 659
Benkert, P., Meier, S., Schaedelin, S. A., Manouchehrinia, A., Yaldizli, Ö., Maceski, A. M., Oechtering, J., Achtnichts, L., Conen, D., Derfuss, T. J., et al. (2022) · UCL Discovery (University College London) · doi:10.48350/165754 · Cited by 458
Hohlfeld, R. (1997) · Brain · doi:10.1093/brain/120.5.865 · Cited by 363
The Immune Response in Multiple Sclerosis
Murúa, S. R., Farez, M., & Quintana, F. J. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052920-040318 · Cited by 378
Metadata
- Authors
- Hauser, S. L., & Cree, B. A. C.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Hauser, Stephen L.
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 133
- Issue
- 12
- Pages
- 1380-1390.e2
- ISSN
- 0002-9343 (ISSN-L)
- PMC
- PMC7704606
- OpenAlex
- W3042308502
- Cited by
- 969
- References
- 81
- Citations by year
- 2026: 149 · 2025: 208 · 2024: 229 · 2023: 175 · 2022: 135 · 2021: 64 · 2020: 7
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The American Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Novartis
- Roche
- National Institute of Neurological Disorders and Stroke (R35NS111644)
- TG Therapeutics
- Valhalla Foundation
- National Multiple Sclerosis Society (RR 2005-A-13)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- multiple sclerosis, relapsing-remitting multiple sclerosis, disease-modifying therapy, B-cell therapy, T cell-mediated autoimmunity, neurodegeneration, disability progression, symptom management, first-line therapy, long-term prognosis
- MeSH terms
- Antibodies, Monoclonal, Humans, Immunosuppressive Agents, Multiple Sclerosis, Physical Therapy Modalities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
